Sitryx Therapeutics is focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases. The company is building a broad, differentiated pipeline of proprietary therapies by identifying targeted approaches based on how changes in metabolism modulate immune cell function. Sitryx plans to use the new proceeds to progress its immunometabolism-targeting therapies into clinical development. Founded in 2018 by researchers including Houman Ashrafian, Luke O’Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak, the company is led by CEO Neil Weir. Sitryx has prior financing history including seed funding from SV Health Investors and a $30 million Series A, and in 2020 it entered an exclusive global licensing and research collaboration with Eli Lilly, which also became an investor. Sitryx focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The company was founded in 2016 by six researchers and is headquartered in Oxford, UK. Sitryx says it has a pipeline of projects at multiple stages of drug discovery, including two lead programs. Under the agreement with Eli Lilly, Sitryx will grant an exclusive worldwide license to develop and commercialize up to four immunometabolism-targeted therapeutics. The deal pairs Sitryx-led discovery with Lilly-funded and -managed clinical development and commercialization through a five-year research collaboration. Financially, Sitryx will receive a $50 million upfront payment and a $10 million equity investment and is eligible for development and commercialization milestones and royalties. Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease‑modifying therapeutics in immuno‑oncology and immuno‑inflammation. The company has built a pipeline of discovery‑stage projects across oncology and immuno‑inflammatory indications using differentiated chemistry approaches including small molecules, PROTACs and topical formulations. Sitryx’s proprietary science is supported through close collaboration with GSK, including access to certain GSK technologies and licensing of intellectual property and chemical matter. The company was founded with seed funding from SV Health Investors and has recruited experienced drug discovery leadership including CEO Neil Weir. Sitryx closed a $30 million Series A to advance its immunometabolism platform and develop disease‑modifying therapies. It is headquartered in Oxford, UK, and aims to leverage world‑leading academic founders and GSK drug discovery expertise to become a leader in immunometabolism.

Total raised

$79M

Funding rounds

3

Latest round

Equity

Latest activity

Sep 2023